After enduring a two-year diagnostic odyssey, Gregory Maassen received a diagnosis of a postinfectious form of peripheral ...
Lancs Live on MSN
Pins and needles warning issued by BBC's Dr Xand in 'see a GP' alert
Morning Live's Dr Xand van Tulleken discussed common causes of pins and needles and when to worry ...
As Gregory Maassen, Ph.D., prepares to e-bike more than 5,800 miles across the country, he's using the same sense of adventure and skills that he drew ...
We are very pleased to have aligned with the FDA on the path forward for our MAGNITUDE clinical trial, with measures designed to further enhance patient safety and allow us to continue to investigate ...
Dr Xand shared common causes of pins and needles that should be a concern and warrant booking a GP appointment. The list ...
Alnylam Canada ULC is pleased to announce it has received a positive recommendation from Canada's Drug Agency (CDA) for the public reimbursement of its RNAi therapeutic, AMVUTTRA®.1 In December 2025, ...
HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half ...
While vigilant foot care can lead to a reduction in itching, the most important thing you can do is work on improved blood sugar control.
A growing body of neurological research suggests that popular supplement combinations marketed for brain health may actually ...
News Commentary - The global anti-aging therapy market is gaining serious momentum as people live longer and actively look ...
In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...
The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results